Abstract

Recent progress in diabetes mellitus therapy has focused attention on generation of surrogate β-cells from mesenchymal stem cells (MSCs) derived adult tissues. In this study, we conducted a phase I clinical trial in patients with type 2 diabetes mellitus in various age between 30- 79 years old who were treated with autologous adipose-derived MSCs transplantation. MSCs injected into diabetic patients through catheterization then we measured levels of fasting blood glucose, 2h postprandial blood glucose, insulin, c-peptide pre and post stem cell transplantation, also HbA1c. Levels of blood glucose (fasting and 2h post prandial) and insulin were absolutely decreasing after injection. Meanwhile, level of c-peptide was increasing after injection. Level of HbA1c was significantly decreasing after 3 months injection. Thus, adipose-derived mesenchymal stem cells for treatment tertiary failure diabetes mellitus type 2 was better than insulin treatment only.

Original languageEnglish
Pages (from-to)91-95
Number of pages5
JournalJournal of Biomimetics, Biomaterials and Biomedical Engineering
Volume31
DOIs
Publication statusPublished - 2017

Keywords

  • Adipose tissue
  • Autologous
  • Diabetes mellitus type 2
  • Mesenchymal stem cells

Fingerprint

Dive into the research topics of 'Adipose-derived mesenchymal stem cells for treatment tertiary failure diabetes mellitus type 2'. Together they form a unique fingerprint.

Cite this